TITLE

Insulin glargine overdose

AUTHOR(S)
Doğan, Fatma Sarı; Onur, Özge Ecmel; Altınok, Arzu Denizbaşı; Güneysel, Özlem
PUB. DATE
October 2012
SOURCE
Journal of Pharmacology & Pharmacotherapeutics;Oct-Dec2012, Vol. 3 Issue 4, p333
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual. Insulin glargine is given as a 24-h dosing regimen and has no documented half-life or peak effect. Hypoglycemia is the most common adverse effect of insulin, including insulin glargine. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. We present a case of a 76-year-old male insulin-dependent diabetic patient with refractory hypoglycemia secondary to an intentional overdose of insulin glargine. We would like to highlight the necessity of prolonging IV glucose infusion, for a much longer period than expected from pharmacokinetic properties of these insulin analogues after intentional massive overdose.
ACCESSION #
84535781

 

Related Articles

  • Group action on insulin faces collapse. Dyer, Clare // BMJ: British Medical Journal (International Edition);3/27/93, Vol. 306 Issue 6881, p814 

    Reports the legal action of diabetic patients against the genetically engineered human insulin manufactured by pharmaceutical industry in Great Britain. Harmful effects of the product; Comparison of the biological effects between human and animal insulin; Factors contributing to the...

  • Insulin: A Voice for Choice. Teuscher, Arthur // Diabetes Health;Dec2007/Jan2008, Vol. 16 Issue 6, p18 

    The article discusses the dangers of hypoglycemic unawareness in diabetics who are taking human insulin. Human insulin came into use in the 1980s as a more physiological alternative to animal insulin, but some patients however reported a sudden loss of symptoms that had previously warned them...

  • Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Hirschberg, Raimund; Kopple, Joel; Lipsett, Pamela; Benjamin, Ernest; Minei, Joseph; Albertson, Timothy; Munger, Mark; Metzler, Michael; Zaloga, Gary; Murray, Michael; Lowry, Stephen; Conger, John; Mckeown, Wade; O'Shea, Michael; Baughman, Robert; Wood, Kenneth; Haupt, Marilyn; Kaiser, Roger; Simms, Hank; Warnock, David // Kidney International;Jun1999, Vol. 55 Issue 6, p2423 

    Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Background. Patients with acute renal failure (ARF) have high morbidity and mortality rates, particularly if they have serious comorbid conditions. Several studies indicate that in...

  • insulin aspart.  // Royal Society of Medicine: Medicines;2002, p305 

    The article presents information on insulin aspart, a recombinant biosynthetic human insulin analogue, which is used in diabetic treatment to maintain diabetic patients. Insulin aspart has a faster rate of onset and offset of action than soluble insulin. Administration is by injection.

  • insulin lispro.  // Royal Society of Medicine: Medicines;2002, p305 

    The article presents information on insulin lispro, a recombinant biosynthetic human insulin analogue, which is used in diabetic treatment to maintain diabetic patients. Insulin lispro is relatively short-acting. Administration is by injection.

  • Scientific study confirms the safety and prebiotic effect of OraftiSynergy1 in infants.  // Food Engineering & Ingredients;May/Jun2014, Vol. 39 Issue 2, p20 

    The article reports on the scientific study in the safety use of BONEO's OraftiSynergyl for infant formula which is rich in oligofructose enriched insulin.

  • A Case of Suppurative Granuloma Induced by Insulin Injection. Tanizaki, Hideaki; Matsumura, Vumi; Tokura, Yoshiki; Miyachi, Yoshiki; Kabashim, Kenji // Acta Dermato-Venereologica;2010, Vol. 90 Issue 5, p540 

    The article presents a case study of a 76-year-old woman with diabetes mellitus presenting with multiple deep-seated, slightly pruritic, symmetrical skin nodules on the flanks and thighs. She claimed that the lesion appeared two-three days after insulin injections. A skin biopsy of an...

  • Recombinant human proinsulin expression in Pichiapastoris using PGK promoter. de Assunçao, Enedina Nogueira; Cristina dos, Santos Maria; Araripe, Torres Fernando; Spartaco, Astolfi-Filho // BMC Proceedings;10/1/2014, p1 

    An abstract of the article "Recombinant human proinsulin expression in Pichiapastoris using PGK promoter" by Torres Fernando Araripe and colleagues is presented.

  • CLINICAL CONSULTATION. Use of concentrated insulin human regular (U-500) for patients with diabetes. Segal, Alissa R.; Brunner, Jack E.; Burch, F. Taylor; Jackson, Jeffrey A. // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1526 

    Purpose. The efficacy and safety of and key clinical considerations for using U-500 insulin human regular in the treatment of high-dose insulin-treated patients in a wide variety of settings are examined. Summary. U-500 regular insulin has been available in the United States since 1952, but only...

  • Yeast secretory expression of insulin precursors. Kjeldsen, T. // Applied Microbiology & Biotechnology;Sep2000, Vol. 54 Issue 3, p277 

    Since the 1980s, recombinant human insulin for the treatment of diabetes mellitus has been produced using either the yeast Saccharomyces cerevisiae or the prokaryote Escherichia coli. Here, development of the insulin secretory expression system in S. cerevisiae and its subsequent optimisation is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics